The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
Open accessAbstract
Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000’s. The path to the commercialization of oncology drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development. The pace at which pharmaceutical companies have formed partnerships to use proprietary nanoparticle technologies has considerably accelerated. It is now recognized that by enhancing the efficacy and/or tolerability of new drug candidates, nanotechnology can meaningfully contribute to create differentiated products and improve clinical outcome. This review describes the lessons learned since the commercialization of the first-generation nanomedicines including DOXIL® and Abraxane®. It explores our current understanding of targeted and non-targeted nanoparticles that are under various stages of development, including BIND-014 and MM-398. It highlights the opportunities and challenges faced by nanomedicines in contemporary oncology, where personalized medicine is increasingly the mainstay of cancer therapy. We revisit the fundamental concepts of enhanced permeability and retention effect (EPR) and explore the mechanisms proposed to enhance preferential “retention” in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages. The overall objective of this review is to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–302 of 302
Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules
Netti, P. A., Hamberg, L. M., Babich, J. W., Kierstead, D., Graham, W., Hunter, G. J., Wolf, G. L., Fischman, A., Boucher, Y., & Jain, R. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3137 · Cited by 202
PLGA Nanoparticle−Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1
Zhang, N., Chittasupho, C., Duangrat, C., Siahaan, T. J., & Berkland, C. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700227z · Cited by 198
Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins
Goodman, S. L., Hölzemann, G., Sulyok, G. A. G., & Kessler, H. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0102598 · Cited by 196
Fahmy, T. M., Samstein, R. M., Harness, C. C., & Mark Saltzman, W. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.02.025 · Cited by 194
Schmitt‐Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B. G., Teifel, M., Michaelis, U., Naujoks, K., & Dellian, M. (2003) · PubMed · Cited by 192
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
Geisberg, C. A., & Sawyer, D. B. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0146-y · Cited by 189
Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif
Colombo, G., Curnis, F., De Mori, G. M. S., Gasparri, A., Longoni, C., Sacchi, A., Longhi, R., & Corti, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207500200 · Cited by 188
Koukourakis, M. I., Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S., & Karkavitsas, N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1459 · Cited by 186
Valencia, P. M., Hanewich-Hollatz, M. H., Gao, W., Karim, F., Langer, R., Karnik, R., & Farokhzad, O. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.078 · Cited by 184
Self-citationCombinatorial Drug Conjugation Enables Nanoparticle Dual‐Drug Delivery
Aryal, S., Hu, C. J., & Zhang, L. (2010) · Small · doi:10.1002/smll.201000631 · Cited by 183
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials
Scheinberg, D. A., Villa, C. H., Escorcia, F. E., & McDevitt, M. R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.38 · Cited by 180
“Targeting” nanoparticles: The constraints of physical laws and physical barriers
Florence, A. T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.022 · Cited by 179
Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
Duncan, R., Vicent, M. J., Greco, F., & Nicholson, R. I. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01045 · Cited by 179
Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors
Alexandrakis, G., Brown, E. B., Tong, R. T., McKee, T. D., Campbell, R. B., Boucher, Y., & Jain, R. K. (2004) · Nature Medicine · doi:10.1038/nm981 · Cited by 178
Werner, M. E., Karve, S., Sukumar, R., Cummings, N. D., Copp, J. A., Chen, R. C., Zhang, T., & Wang, A. Z. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.067 · Cited by 176
Kleiner, R. E., Dumelin, C. E., Tiu, G. C., Sakurai, K., & Liu, D. R. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104903x · Cited by 173
Aptamer-Functionalized Nanoparticles for Medical Applications: Challenges and Opportunities
Xiao, Z., & Farokhzad, O. C. (2012) · ACS Nano · doi:10.1021/nn301869z · Cited by 172
Self-citationCell-specific delivery of genes with glycosylated carriers
HASHIDA, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00209-5 · Cited by 171
van Osdol, W. W., Fujimori, K., & Weinstein, J. N. (1991) · PubMed · Cited by 170
HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy
Alexis, F., Basto, P., Levy‐Nissenbaum, E., Radovic‐Moreno, A. F., Zhang, L., Pridgen, E., Wang, A. Z., Marein, S. L., Westerhof, K., Molnar, L. K., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200800122 · Cited by 164
Self-citationTekle, C., van Deurs, B., Sandvig, K., & Iversen, T. (2008) · Nano Letters · doi:10.1021/nl0803848 · Cited by 164
Nanoparticulate drug delivery systems for cancer chemotherapy
Saha, R. N., Vasanthakumar, S., Bende, G., & Snehalatha, M. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.510804 · Cited by 163
LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors
Luo, G., Yu, X., Jin, C., Yang, F., Fu, D., Long, J., Xu, J., Zhan, C., & Lu, W. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.10.014 · Cited by 161
Cortés, J., & Saura, C. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)70002-1 · Cited by 161
Targeted nanoparticles with novel non-peptidic ligands for oral delivery
Rieux, A. D., Pourcelle, V., Cani, P. D., Marchand‐Brynaert, J., & Véronique Préat, A. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.01.002 · Cited by 159
Shukla, S., Ablack, A. L., Wen, A. M., Lee, K. L., Lewis, J. D., & Steinmetz, N. F. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300240m · Cited by 158
Xiao, Z., Levy‐Nissenbaum, E., Alexis, F., Lupták, A., Teply, B. A., Chan, J. M., Shi, J., Digga, E., Cheng, J. W. M., Langer, R., et al. (2012) · ACS Nano · doi:10.1021/nn204165v · Cited by 157
Self-citationLigand‐Clustered “Patchy” Nanoparticles for Modulated Cellular Uptake and In Vivo Tumor Targeting
Poon, Z., Chen, S., Engler, A. C., Lee, H., Atas, E., von Maltzahn, G., Bhatia, S. N., & Hammond, P. T. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201003445 · Cited by 156
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)
Danhauser-riedl, S., Hausmann, E., Schick, H.-D., Bender, R., Dietzfelbinger, H., Rastetter, J., & Hanauske, A.-R. (1993) · Investigational New Drugs · doi:10.1007/bf00874153 · Cited by 152
Chan, J. M., Rhee, J., Drum, C. L., Bronson, R. T., Golomb, G., Langer, R., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115945108 · Cited by 143
Self-citationFisher, R. E., Siegel, B. A., Edell, S. L., Oyesiku, N. M., Morgenstern, D. E., Messmann, R. A., & Amato, R. J. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.049478 · Cited by 143
Stylianopoulos, T., Soteriou, K., Fukumura, D., & Jain, R. K. (2012) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0630-4 · Cited by 141
Nomura, T., Koreeda, N., Yamashita, F., Takakura, Y., & Hashida, M. (1998) · Pharmaceutical Research · doi:10.1023/a:1011921324952 · Cited by 135
Extravasation of macromolecules
Takakura, Y., Mahato, R. I., & Hashida, M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00006-4 · Cited by 134
Koukouraki, A. M. I. K. S. (2000) · Acta Oncologica · doi:10.1080/028418600430789 · Cited by 128
Kano, M. R., Komuta, Y., Iwata, C., Oka, M., Shirai, Y.-T., Morishita, Y., Ouchi, Y., Kataoka, K., & Miyazono, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01003.x · Cited by 125
Targeted therapies: how personal should we go?
Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 124
Koshkaryev, A., Sawant, R. R., Deshpande, M., & Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.009 · Cited by 122
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
Schoemaker, N. E., van Kesteren, C., Rosing, H., Jansen, S., Swart, M., Lieverst, J. A., Fraier, D., Breda, M., Pellizzoni, C., Spinelli, R., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600516 · Cited by 122
Recent developments in carbohydrate‐decorated targeted drug/gene delivery
Zhang, H., Ma, Y., & Sun, X. (2009) · Medicinal Research Reviews · doi:10.1002/med.20171 · Cited by 119
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
La-Beck, N. M., Zamboni, B. A., Gabizón, A., Schmeeda, H., Amantea, M., Gehrig, P. A., & Zamboni, W. C. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1664-2 · Cited by 118
Liu, Y., Tseng, Y.-C., & Huang, L. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0818-1 · Cited by 116
Phase 0 Clinical Trials: Conceptions and Misconceptions
Kummar, S., Rubinstein, L., Kinders, R. J., Parchment, R. E., Gutierrez, M. E., Murgo, A. J., Ji, J., Mroczkowski, B., Pickeral, O. K., Simpson, M., et al. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d6f3 · Cited by 111
Löhr, M. J., Haas, S., Bechstein, W. O., Bodoky, G., Cwiertka, K., Fischbach, W., Fölsch, U. R., Jäger, D., Osinsky, D., Prausová, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr379 · Cited by 108
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing
Ong, F. S.-C., Das, K., Wang, J., Vakil, H., Kuo, J., Blackwell, W.-L. B., Lim, S. W., Goodarzi, M. O., Bernstein, K. E., Rotter, J. I., et al. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.59 · Cited by 108
Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion
Silvius, J. R., & Zuckermann, M. J. (1993) · Biochemistry · doi:10.1021/bi00063a030 · Cited by 106
Fasol, U., Frost, A., Büchert, M., Arends, J., Fiedler, U., Scharr, D., Scheuenpflug, J., & Mross, K. B. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr300 · Cited by 101
Wu, J., Wu, D., Mutschler, M. A., & Chu, C. (2012) · Advanced Functional Materials · doi:10.1002/adfm.201103147 · Cited by 100
Self-citationYurkovetskiy, A., & Fram, R. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.01.007 · Cited by 100
Delehanty, J. B., Boeneman, K., Bradburne, C. E., Robertson, K. L., Bongard, J. E., & Medintz, I. L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.27 · Cited by 100
Imaging Nanoprobe for Prediction of Outcome of Nanoparticle Chemotherapy by Using Mammography
Karathanasis, E., Suryanarayanan, S., Balusu, S. R., McNeeley, K. M., Sechopoulos, I., Karellas, A., Annapragada, A., & Bellamkonda, R. V. (2009) · Radiology · doi:10.1148/radiol.2502080801 · Cited by 97
EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
Winkler, J., Martin-Killias, P., Plückthun, A., & Zangemeister‐Wittke, U. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0402 · Cited by 97
In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes
Han, H., LEE, A., SONG, C., HWANG, T., Seong, H., Lee, C.-L., & SHIN, B. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.007 · Cited by 93
Protonated Nanoparticle Surface Governing Ligand Tethering and Cellular Targeting
Vincent, A., Babu, K. S., Heckert, E. G., Dowding, J. M., Hirst, S. M., Инербаев, Т. М., Self, W. T., Reilly, C. M., Masunov, A. E., Rahman, T. S., et al. (2009) · ACS Nano · doi:10.1021/nn9000148 · Cited by 91
Spatial Charge Configuration Regulates Nanoparticle Transport and Binding Behavior In Vivo
Han, H., Martin, J. D., Lee, J., Harris, D. K., Fukumura, D., Jain, R. K., & Bawendi, M. G. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201208331 · Cited by 91
Organic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer
Shi, M., Lu, J., & Shoichet, M. S. (2009) · Journal of Materials Chemistry · doi:10.1039/b822319j · Cited by 90
Fang, J. Q., Qin, H., Nakamura, H., Tsukigawa, K., Shin, T., & Maeda, H. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02178.x · Cited by 88
Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates
Park, J. Y., Mattessich, T., Jay, S. M., Agawu, A., Saltzman, W. M., & Fahmy, T. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.025 · Cited by 87
Chen, H., Paholak, H. J., Ito, M., Sansanaphongpricha, K., Qian, W. P., Che, Y., & Sun, D. (2013) · Nanotechnology · doi:10.1088/0957-4484/24/35/355101 · Cited by 85
Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells.
Leserman, L., Weinstein, J. N., Blumenthal, R. P., & Terry, W. D. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.4089 · Cited by 83
Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles
Valencia, P. M., Pridgen, E. M., Perea, B., Gadde, S., Sweeney, C. J., Kantoff, P. W., Bander, N. H., Lippard, S. J., Langer, R., Karnik, R., et al. (2012) · Nanomedicine · doi:10.2217/nnm.12.134 · Cited by 83
Self-citationChawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Blackwelder, W. C., Gordon, E. M., & Hall, F. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.228 · Cited by 81
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D. V. K., Saralou, A., Blackwelder, W. C., Hall, F. L., & Gordon, E. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.126 · Cited by 79
Water insoluble cationic poly(ester amide)s: synthesis, characterization and applications
Wu, J., & Chu, C. (2012) · Journal of Materials Chemistry B · doi:10.1039/c2tb00070a · Cited by 79
Self-citationAllen, T. M., Newman, M. S., Woodle, M. C., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620215 · Cited by 79
Nishida, K., Mihara, K., Takino, T., Nakane, S., Takakura, Y., Hashida, M., & Sezaki, H. (1991) · Pharmaceutical Research · doi:10.1023/a:1015886708598 · Cited by 75
Hamaguchi, T., Matsumura, Y., Nakanishi, Y., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Niki, H., Hosokawa, S., Tagawa, T., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02495.x · Cited by 74
Ligand density and clustering effects on endocytosis of folate modified nanoparticles
Moradi, E., Vllasaliu, D., Garnett, M. C., Falcone, F. H., & Stolnik, S. (2012) · RSC Advances · doi:10.1039/c2ra01168a · Cited by 71
Bertrand, N., Fleischer, J. G., Wasan, K. M., & Leroux, J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.082 · Cited by 69
Self-citationPoly(ethylene glycol) with Observable Shedding
Gao, W., Langer, R., & Farokhzad, O. C. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201001868 · Cited by 68
Self-citationInterpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents
Caron, W. P., Song, G. J., Kumar, P., Rawal, S., & Zamboni, W. C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.12 · Cited by 68
Strieth, S., Eichhorn, M., Werner, A., Sauer, B., Teifel, M., Michaelis, U., Berghaus, A., & Dellian, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4738 · Cited by 68
Singh, R., Kats, L., Blättler, W. A., & Lambert, J. M. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0139 · Cited by 66
The role of hepatocytes in the clearance of liposomes from the blood circulation
Scherphof, G. L., & Kamps, J. A. A. M. (2001) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00020-5 · Cited by 65
Maeda, H. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.002 · Cited by 64
Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy
Saw, P. E., Kim, S., Lee, I., Park, J., Yu, M., Lee, J., Kim, J., & Jon, S. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20815j · Cited by 63
Wu, J., & Chu, C. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.07.027 · Cited by 60
Self-citationAntibody Engineering Promotes Nanomedicine for Cancer Treatment
Gao, J., Feng, S., & Guo, Y. (2010) · Nanomedicine · doi:10.2217/nnm.10.94 · Cited by 59
Preclinical safety testing of biotechnology-derived pharmaceuticals
Brennan, F., Shaw, L., Wing, M., & Robinson, C. (2004) · Molecular Biotechnology · doi:10.1385/mb:27:1:59 · Cited by 58
Murakami, Y., Tabata, Y., & Ikada, Y. (1997) · Drug Delivery · doi:10.3109/10717549709033184 · Cited by 51
Galanis, E., Carlson, S. K., Foster, N. R., Lowe, V. J., Quevedo, F., McWilliams, R. R., Grothey, A. F., Jatoi, A., Alberts, S. R., & Rubin, J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.29 · Cited by 50
In VivoEvaluation of pH-Sensitive Polymer-Based Immunoliposomes Targeting the CD33 Antigen
Simard, P., & Leroux, J. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900261m · Cited by 47
André, S., Frisch, B., Kaltner, H., de Souza, D. L., Schuber, F. J., & Gabius, H. (2000) · Pharmaceutical Research · doi:10.1023/a:1007535506705 · Cited by 46
Papademetriou, I. T., Garnacho, C., Schuchman, E. H., & Muro, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.069 · Cited by 46
Ansell, S. M., Tardi, P. G., & Buchkowsky, S. S. (1996) · Bioconjugate Chemistry · doi:10.1021/bc960036+ · Cited by 45
Zamboni, W. C., Maruca, L. J., Strychor, S., Zamboni, B. A., Ramalingam, S. S., Edwards, R. P., Kim, J., Bang, Y., Lee, H., Friedland, D., et al. (2010) · Journal of Liposome Research · doi:10.3109/08982104.2010.496085 · Cited by 45
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen
Slovin, S. F. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.561 · Cited by 44
Burke, C. W., Suk, J. S., Kim, A. J., Hsiang, Y.-H. J., Klibanov, A. L., Hanes, J. S., & Price, R. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.005 · Cited by 43
Attempted targeting of a monoclonal antibody in a human tumour xenograft system
Warenius, H. M., Galfré, G., Bleehen, N. M., & Milstein, C. (1981) · European Journal of Cancer and Clinical Oncology · doi:10.1016/s0277-5379(81)80006-5 · Cited by 42
Allometric scaling of pegylated liposomal anticancer drugs
Caron, W. P., M.A., H. J. C. I., Dedrick, R. L., Ramanathan, R. K., Davis, W. L., Yu, N. Y., Tonda, M. E., Schellens, J. H. M., Beijnen, J. H., & Zamboni, W. C. (2011) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9213-5 · Cited by 41
The macroscopic and microscopic pharmacology of monoclonal antibodies
Weinstein, J. N., & van Osdol, W. (1992) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(92)90176-l · Cited by 34
Sun, M., Yang, L., Jose, P., Wang, L., & Zweit, J. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20894j · Cited by 33
Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., Tsurumi, H., Takashina, K., & Maeda, H. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb00093.x · Cited by 32
Zamboni, W. C., Eiseman, J. L., Strychor, S., Rice, P. M., Joseph, E., Zamboni, B. A., Donnelly, M. K., Shurer, J., Parise, R. A., Tonda, M. E., et al. (2010) · Journal of Liposome Research · doi:10.3109/08982101003754385 · Cited by 28
A simple method for introducing a thiol group at the 5′-end of synthetic oligonucleotides
Kumar, A., Adwani, S., Dawar, H., & Talwar, G. P. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.16.4561 · Cited by 24
Wickham, T. J., & Futch, K. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p5-18-09 · Cited by 23
Münster, P. N., Miller, K. D., Krop, I. E., Dhindsa, N., Reynolds, J., Geretti, E., Niyikiza, C., Nielsen, U. B., Hendriks, B. S., Wickham, T. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps663 · Cited by 23
Nanoparticle-Mediated Measurement of Target–Drug Binding in Cancer Cells
Ullal, A. V., Reiner, T., Yang, K. S., Gorbatov, R., Min, C., Issadore, D., Lee, H., & Weissleder, R. (2011) · ACS Nano · doi:10.1021/nn203450p · Cited by 22
Potential of Advexin ® : A p53 Gene-Replacement Therapy in Li–Fraumeni Syndrome
Nemunaitis, J., & Nemunaitis, J. J. (2008) · Future Oncology · doi:10.2217/14796694.4.6.759 · Cited by 15
Leckband, D. E. (2011) · Current Protein and Peptide Science · doi:10.2174/138920311798841735 · Cited by 4
Tuma, R. S. (2013) · Oncology Times · doi:10.1097/01.cot.0000427826.53087.1a · Cited by 2
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationClinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Self-citationPhotothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
Liu, Y., Bhattarai, P., Dai, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00618k · Cited by 2,904
Metadata
- Authors
- Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 66
- Pages
- 2-25
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2153771870
- Cited by
- 2,824
- References
- 302
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.